CompletedNCT02697045
Long-Acting Aripiprazole and Daily Functioning in Schizophrenia
About this title
Read the official source — NCT02697045Medication studyAges 18–45Türkiye
Understand this study
Who was this study for?
Listed age limits: 18 years to 45 years.
- Listed locations
- Adana and 14 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: January 4, 2017
- Recruitment status
- Completed
- Enrollment listed in the registry
- 23
- Sponsor
- Abdi İbrahim Otsuka
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Türkiye
- Age range
- From 18 Years to 45 Years
- Official registry ID
- NCT02697045
- Official title
Show the full official title
Nautralsitic, Open-label, Single Arm Study Evaluating Effects of Aripiprazole LAI on Phychosocial&Congitive Functioning, Patient Reported Acceptability of Treatment Regarding QoL, Subjective Well-being Under Neuroleptic Medication in Sch
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Adana, Türkiye · Ankara, Türkiye · Bursa, Türkiye
8 more locations
- Istanbul, Türkiye
- Izmir, Türkiye
- Kocaeli, Türkiye
- Konya, Türkiye
- Manisa, Türkiye
- Mersin, Türkiye
- Samsun, Türkiye
- Türkiye
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Abdi İbrahim Otsuka.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole 400mg LAI.
Who was this study for?
Listed age limits: 18 years to 45 years.
